Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

284 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.
Combe B, Dasgupta B, Louw I, Pal S, Wollenhaupt J, Zerbini CA, Beaulieu AD, Schulze-Koops H, Durez P, Yao R, Vastesaeger N, Weng HH; GO-MORE Investigators. Combe B, et al. Ann Rheum Dis. 2014 Aug;73(8):1477-86. doi: 10.1136/annrheumdis-2013-203229. Epub 2013 Jun 5. Ann Rheum Dis. 2014. PMID: 23740226 Free PMC article. Clinical Trial.
Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol.
Mueller RB, Spaeth M, von Restorff C, Ackermann C, Schulze-Koops H, von Kempis J. Mueller RB, et al. J Clin Med. 2019 Mar 3;8(3):302. doi: 10.3390/jcm8030302. J Clin Med. 2019. PMID: 30832414 Free PMC article.
Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM).
Mueller RB, Reshiti N, Kaegi T, Finckh A, Haile SR, Schulze-Koops H, Schiff M, Spaeth M, von Kempis J; SCQM physicians. Mueller RB, et al. Clin Rheumatol. 2017 Jan;36(1):59-66. doi: 10.1007/s10067-016-3468-6. Epub 2016 Nov 12. Clin Rheumatol. 2017. PMID: 27838788 Free article.
284 results